CSIMarket


Aurinia Pharmaceuticals Inc   (NASDAQ: AUPH)
Other Ticker:  
 

Aurinia Pharmaceuticals Inc

AUPH's Fundamental analysis








Looking into Aurinia Pharmaceuticals Inc growth rates, revenue grew by 24.32 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 596

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Aurinia Pharmaceuticals Inc realized net income compared to net loss a year ago in III. Quarter 2024

More on AUPH's Growth


Aurinia Pharmaceuticals Inc
realized a net loss in trailing twelve months.

Aurinia Pharmaceuticals Inc realized cash reduction of $ -0.06 per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.29.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.


More on AUPH's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 4,590,854
 Net Income/Employee (TTM) $ -469,833
 Receivable Turnover (TTM) 7.66
 Tangible Book Value (Per Share $) 2.63

Aurinia Pharmaceuticals Inc
realized net loss in trailing twelve months.

Aurinia Pharmaceuticals Inc realized cash outflow of $ -0.06per share in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 5.29.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.

Aurinia Pharmaceuticals Inc Price to Book Ratio is at 3.01 lower than Industry Avg. of 89.07. and higher than S&P 500 Avg. of 0.01

More on AUPH's Valuation

  Market Capitalization (Millions $) 1,167
  Shares Outstanding (Millions) 146
  Employees 48
  Revenues (TTM) (Millions $) 220
  Net Income (TTM) (Millions $) -23
  Cash Flow (TTM) (Millions $) -9
  Capital Exp. (TTM) (Millions $) 0
  Total Debt (Millions $) -
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 4,590,854
  Net Income/Employee(TTM) $ -469,833
  Receivable Turnover Ratio (TTM) 7.66
  Tangible Book Value (Per Share $) 2.63

  Market Capitalization (Millions $) 1,167
  Shares Outstanding (Millions) 146
  Employees 48
  Revenues (TTM) (Millions $) 220
  Net Income (TTM) (Millions $) -23
  Cash Flow (TTM) (Millions $) -9
  Capital Exp. (TTM) (Millions $) 0


    AUPH's Profitability Comparisons
Aurinia Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 17.33 %.

Aurinia Pharmaceuticals Inc net profit margin of 21.17 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 51 in Healthcare sector and number 672 in S&P 500.


Profitability by Segment
Total 21.17 %



  Ratio
   Capital Ratio (MRQ) 5.6
  Total Debt to Equity (MRQ) -
  Tangible Leverage Ratio (MRQ) 0.23
  Asset Turnover Ratio (TTM) 0.41
  Inventory Turnover Ratio (TTM) 0.72



Aurinia Pharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 17.33 %.

Aurinia Pharmaceuticals Inc net profit margin of 21.17 % is currently ranking no. 28 in Major Pharmaceutical Preparations industry, ranking no. 51 in Healthcare sector and number 672 in S&P 500.

More on AUPH's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com